Gain Therapeutics, Inc. Reports Third Quarter 2022 Financial Results and Business Update
BETHESDA, Md., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule treatments, today announced its financial results for the third quarter ended September 30, 2022, and highlighted recent corporate progress.
- The latest preclinical data provide further validation of the potential utility of our approach and mechanism of action of GT-02287.
- If these results are supported in our upcoming clinical trials, we believe that GT-02287 could become a potential first-in-class disease-modifying therapy for Parkinsons disease.
- Presented new preclinical data for GT-02287, Gains lead compound for Parkinsons Disease at the International Congress of Parkinsons Disease and Movement Disorders 2022 Annual Meeting.
- Cash, cash equivalents and marketable securities were $25.7 million as of September 30, 2022 compared to $36.8 million at December 31, 2021.